AP2005003292A0 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof - Google Patents

Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Info

Publication number: AP2005003292A0
Authority: AP; ARIPO
Prior art keywords: cystic fibrosis; protein inhibitors; fibrosis transmembrane; conductance regulator; transmembrane conductance
Prior art date: 2002-09-30

Application number

AP2005003292A

Other languages

English (en)

Inventor

Alan Verkman

Tonghui Ma

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-30

Filing date

2003-09-30

Publication date

2005-06-30

2002-09-30 Priority claimed from US10/262,573 external-priority patent/US20040063695A1/en

2003-09-30 Application filed by Univ California filed Critical Univ California

2005-06-30 Publication of AP2005003292A0 publication Critical patent/AP2005003292A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Virology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Toxicology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AP2005003292A 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof AP2005003292A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/262,573 US20040063695A1 (en)	2002-09-30	2002-09-30	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US48025303P	2003-06-20	2003-06-20
PCT/US2003/031005 WO2004028480A2 (en)	2002-09-30	2003-09-30	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Publications (1)

Publication Number	Publication Date
AP2005003292A0 true AP2005003292A0 (en)	2005-06-30

Family

ID=32044981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003292A AP2005003292A0 (en)	2002-09-30	2003-09-30	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Country Status (13)

Country	Link
EP (1)	EP1549321A4 (xx)
JP (1)	JP4977319B2 (xx)
KR (1)	KR20050061501A (xx)
CN (1)	CN100356922C (xx)
AP (1)	AP2005003292A0 (xx)
AU (1)	AU2003277162C1 (xx)
BR (1)	BR0314943A (xx)
CA (1)	CA2500498C (xx)
EA (1)	EA009847B1 (xx)
MX (1)	MXPA05003366A (xx)
NZ (1)	NZ538809A (xx)
PL (1)	PL376147A1 (xx)
WO (1)	WO2004028480A2 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2674428T (pt)	2006-04-07	2016-07-14	Vertex Pharma	Modeladores de transportadores de cassetes de ligação de atp
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
KR20100016073A (ko)	2007-04-02	2010-02-12	인스티튜트 포 원월드 헬스	Ｃｆｔｒ 억제제 화합물 및 이의 용도
HUE028426T2 (en) *	2007-08-24	2016-12-28	Vertex Pharma	Isothiazolopyridinones for (inter alia) treating cystic fibrosis
ES2556080T3 (es)	2007-11-16	2016-01-12	Vertex Pharmaceuticals Incorporated	Moduladores de isoquinolina de transportadores de casete de unión a ATP
UA102534C2 (xx)	2007-12-07	2013-07-25	Вертекс Фармасьютикалз Инкорпорейтед	ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ)
MX2010010343A (es) *	2008-03-25	2010-10-15	Univ California	Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.
NZ616097A (en)	2008-03-31	2015-04-24	Vertex Pharma	Pyridyl derivatives as cftr modulators
EP2278879B1 (en)	2008-04-21	2016-06-15	PATH Drug Solutions	Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131951A2 (en)	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
EP2341776A4 (en) *	2008-09-19	2012-05-30	Inst Oneworld Health	COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
US8343976B2 (en)	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
US20120219543A1 (en) *	2009-10-20	2012-08-30	Raphael Scharfmann	Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2711481C2 (ru)	2010-03-25	2020-01-17	Вертекс Фармасьютикалз Инкорпорейтед	ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
NZ602795A (en)	2010-04-07	2015-01-30	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN102917692A (zh)	2010-04-07	2013-02-06	弗特克斯药品有限公司	3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法
CA2797118C (en)	2010-04-22	2021-03-30	Vertex Pharmaceuticals Incorporated	Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
WO2012027247A2 (en)	2010-08-23	2012-03-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
CN102133402B (zh) *	2011-03-24	2013-06-12	首都医科大学附属北京同仁医院	囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用
US9056862B2 (en)	2011-05-10	2015-06-16	National University Corporation Kobe University	Thioxothiazolidine derivative having Ras function inhibitory effect
AU2012335714B2 (en)	2011-11-08	2017-04-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US20130186801A1 (en)	2012-01-25	2013-07-25	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2013290444B2 (en)	2012-07-16	2018-04-26	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
PL2914248T5 (pl)	2012-11-02	2024-01-15	Vertex Pharmaceuticals Incorporated	Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR
FR2999191B1 (fr)	2012-12-12	2016-02-05	Lesaffre & Cie	Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
CA2944140C (en)	2014-04-15	2022-10-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
AU2015328174B2 (en)	2014-10-06	2020-05-21	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN104398509B (zh) *	2014-11-13	2017-01-11	四川大学华西第二医院	CFTR抑制剂CFTRinh-172在制备防治白血病细胞介导的疾病的药物中的应用
CN104788423B (zh) *	2015-03-13	2016-10-26	成都理工大学	一种新的囊性纤维化跨膜传导调节因子抑制剂
CA3009531A1 (en) *	2015-12-24	2017-06-29	The Regents Of The University Of California	5-substituted [1,3,4]thiadiazol-2-amido derivatives and use as cftr reg ulators
JOP20190125B1 (ar)	2016-12-09	2022-03-14	Vertex Pharma	مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
AU2018304168B2 (en)	2017-07-17	2023-05-04	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3085006A1 (en)	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
CA3139930A1 (en) *	2019-06-12	2020-12-17	Alan S. Verkman	Methods of treating bile acid diarrhea

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL108962A (en) *	1989-12-21	1996-12-05	Lilly Co Eli	Use of hydroxybenzyl substituted sulfur containing heterocyclic derivatives a process for their preparation and pharmaceutical compositions containing them
AU1090795A (en) *	1993-11-12	1995-05-29	Cell Therapeutics, Inc.	Method for preventing tissue injury from hypoxia
US6423708B1 (en) *	1996-09-30	2002-07-23	Pfizer Inc	Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) *	1996-09-30	2003-05-15	Пфайзер Інк.	Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
JP2002523371A (ja) *	1998-08-21	2002-07-30	バイロファーマ・インコーポレイテッド	ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法
US6484397B1 (en) *	2000-07-11	2002-11-26	Corning Incorporated	Method of assembling a catalytic converter for use in an internal combustion engine
US20020052396A1 (en) *	2001-04-23	2002-05-02	Bailey Thomas R.	Compounds, compositions and methods for treating or preventing viral infections and associated diseases

2003
- 2003-09-30 CN CNB038233665A patent/CN100356922C/zh not_active Expired - Fee Related
- 2003-09-30 WO PCT/US2003/031005 patent/WO2004028480A2/en not_active Ceased
- 2003-09-30 AU AU2003277162A patent/AU2003277162C1/en not_active Ceased
- 2003-09-30 BR BR0314943-9A patent/BR0314943A/pt not_active IP Right Cessation
- 2003-09-30 NZ NZ538809A patent/NZ538809A/en not_active IP Right Cessation
- 2003-09-30 EP EP03798805A patent/EP1549321A4/en not_active Withdrawn
- 2003-09-30 KR KR1020057005551A patent/KR20050061501A/ko not_active Abandoned
- 2003-09-30 AP AP2005003292A patent/AP2005003292A0/xx unknown
- 2003-09-30 JP JP2004540305A patent/JP4977319B2/ja not_active Expired - Fee Related
- 2003-09-30 MX MXPA05003366A patent/MXPA05003366A/es active IP Right Grant
- 2003-09-30 PL PL03376147A patent/PL376147A1/xx not_active Application Discontinuation
- 2003-09-30 EA EA200500583A patent/EA009847B1/ru not_active IP Right Cessation
- 2003-09-30 CA CA2500498A patent/CA2500498C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2006503853A (ja)	2006-02-02
CA2500498C (en)	2012-08-21
MXPA05003366A (es)	2005-10-05
WO2004028480A3 (en)	2004-07-01
AU2003277162C1 (en)	2009-12-24
NZ538809A (en)	2008-06-30
EP1549321A2 (en)	2005-07-06
WO2004028480A2 (en)	2004-04-08
BR0314943A (pt)	2005-08-02
CN100356922C (zh)	2007-12-26
KR20050061501A (ko)	2005-06-22
PL376147A1 (en)	2005-12-27
CN1684686A (zh)	2005-10-19
EA009847B1 (ru)	2008-04-28
AU2003277162A1 (en)	2004-04-19
CA2500498A1 (en)	2004-04-08
JP4977319B2 (ja)	2012-07-18
AU2003277162B2 (en)	2009-07-16
EA200500583A1 (ru)	2005-12-29
EP1549321A4 (en)	2007-05-23

Publication	Publication Date	Title
AP2005003292A0 (en)	2005-06-30	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AU2003228393A1 (en)	2003-10-13	Ehanced protein expression in bacillus
WO2004040000A9 (en)	2009-08-27	G protein coupled receptors and uses thereof
PL375447A1 (en)	2005-11-28	Protein kinase inhibitors and uses thereof
EP1552002A4 (en)	2006-02-08	APTAMER TOXIN MOLECULES AND METHOD FOR THEIR USE
HUP0301063A3 (en)	2011-05-30	Benzoic-acid isononylesters and applying them
AU2003280084A8 (en)	2004-04-30	Protein arrays and uses thereof
AUPS238502A0 (en)	2002-06-13	Cystic echinococcosis protein and uses therefor
AU2003268023A8 (en)	2004-02-09	Protein modification and maintenance molecules
HK1079695A (en)	2006-04-13	Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
AU2002348834A8 (en)	2003-06-23	Method and system providing user mobility in a mobile-ip-network by means of a personal ip address
AU2003301112A1 (en)	2004-07-14	Hand and fingernail cleaning apparatus
AU2003231981A8 (en)	2003-10-13	Protein modification and maintenance molecules
AU2003239871A8 (en)	2003-12-12	Protein modification and maintenance molecules
AU2003280992A1 (en)	2004-02-02	Novel proteins and use thereof
AU2003291426A8 (en)	2004-06-03	Gp64-pseudotyped vectors and uses thereof
AU2003292774A1 (en)	2004-07-22	Novel proteins and use thereof
AU7080601A (en)	2002-01-30	Activation of the cystic fibrosis transmembrane conductance regulator chloride channel
AU2003260487A8 (en)	2003-10-20	Novel pancortin-pablo protein interactions and methods of use thereof
AU2003202650A1 (en)	2003-12-02	Cystic echinococcosis protein and uses therefor
AU2003249644A8 (en)	2003-12-12	Mutant p53 (delta126-132) protein and uses thereof
EP1549951A4 (en)	2006-08-09	SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF
AU2003270876A8 (en)	2004-04-19	Anti-hla assay and methods
EP1699809A4 (en)	2009-10-21	PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
GB0228538D0 (en)	2003-01-15	Protein structure and uses thereof